UBX Insider Trading

Insider Ownership Percentage: 5.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $8,040.02

Unity Biotechnology Insider Trading History Chart

This chart shows the insider buying and selling history at Unity Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Unity Biotechnology Share Price & Price History

Current Price: $0.99
Price Change: Price Increase of +0.0298 (3.10%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for UBX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.99Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Unity Biotechnology (NASDAQ:UBX)

29.49% of Unity Biotechnology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at UBX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$28kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal InflowsTotal Outflows
Unity Biotechnology logo
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Read More on Unity Biotechnology

Today's Range

Now: $0.99
Low: $0.93
High: $1.02

50 Day Range

MA: $1.58
Low: $0.88
High: $2.30

52 Week Range

Now: $0.99
Low: $0.85
High: $3.10

Volume

59,072 shs

Average Volume

116,971 shs

Market Capitalization

$16.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Who are the company insiders with the largest holdings of Unity Biotechnology?

Unity Biotechnology's top insider shareholders include:
  1. Anirvan Ghosh (CEO)
  2. Lynne Marie Sullivan (CFO)
  3. Alexander Hieu Nguyen (Insider)
Learn More about top insider investors at Unity Biotechnology.

Who are the major institutional investors of Unity Biotechnology?

Unity Biotechnology's top institutional investors include:
  1. SeaCrest Wealth Management LLC — 0.16%
Learn More about top institutional investors of Unity Biotechnology stock.

Which major investors are buying Unity Biotechnology stock?

Within the previous quarter, UBX stock was acquired by institutional investors including:
  1. SeaCrest Wealth Management LLC